细胞遗传学对复发多发性骨髓瘤缓解持续时间和总生存的影响(BSBMT/UKMF Myeloma X 复发[强化]试验的长期随访结果):一项随机、开放标签、3期试验
Myeloma X试验将复发多发性骨髓瘤患者随机分配至挽救性自体干细胞移植(ASCT)或每周环磷酰胺。中位随访76个月时,ASCT较环磷酰胺改善至进展时间(19个月 vs 11个月,HR 0.40)和总生存(67个月 vs 55个月,HR 0.64)。任何单一高危细胞遗传学病变对至进展时间有不利影响,MYC重排对总生存有不利影响。
要点
- ASCT较环磷酰胺改善至进展时间(19个月 vs 11个月,HR 0.40,P<0.001)。
- ASCT较环磷酰胺改善总生存(67个月 vs 55个月,HR 0.64,P=0.0435)。
- 高危细胞遗传学病变对至进展时间有不利影响(LRT P=0.011),MYC重排对总生存有不利影响(LRT P=0.021)。
核心结论
- 分析进一步支持挽救性ASCT的获益,在存活患者的第二次复发后可能仍有益。
- 有证据表明该获益在细胞遗传学高危患者中降低,突显需要在该患者群体中进行靶向研究。
研究设计与样本
- Myeloma X试验(ISCRTN60123120)纳入复发多发性骨髓瘤患者,随机分配至挽救性自体干细胞移植(ASCT)或每周环磷酰胺(再诱导治疗后)。
- 试验注册时进行的细胞遗传学分析将t(4;14)、t(14;16)和del(17p)定义为高危。
- 研究中位随访76个月,分析细胞遗传学对至进展时间(TTP)和总生存(OS)的影响。
主要发现
- ASCT组至进展时间19个月(95%CI 16-26)vs 环磷酰胺组11个月(95%CI 9-12),HR 0.40(95%CI 0.29-0.56),P<0.001。
- 任何单一高危病变对至进展时间有不利影响(似然比检验LRT P=0.011)。
- ASCT组总生存67个月(95%CI 59-未达到)vs 环磷酰胺组55个月(95%CI 44-67),HR 0.64(95%CI 0.42-0.99),P=0.0435。
- MYC重排对总生存有不利影响(LRT P=0.021)。
- 21例(24.7%)环磷酰胺组患者试验后接受ASCT,这些患者中位总生存未达到(95%CI 39-未达到),而未接受试验后ASCT者中位总生存31个月(95%CI 22-39)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Myeloma X trial (ISCRTN60123120) registered patients with relapsed multiple myeloma. Participants were randomised between salvage autologous stem cell transplantation (ASCT) or weekly cyclophosphamide following re-induction therapy. Cytogenetic analysis performed at trial registration defined t(4;14), t(14;16) and del(17p) as high-risk. The effect of cytogenetics on time to progression (TTP) and overall survival was investigated. At 76 months median follow-up, ASCT improved TTP compared to cyclophosphamide (19 months (95% confidence interval [95% CI] 16-26) vs. 11 months (9-12), hazard ratio [HR]: 0·40, 95% CI: 0·29-0·56, P < 0·001), on which the presence of any single high-risk lesion had a detrimental impact [likelihood ratio test (LRT): P = 0·011]. ASCT also improved OS [67 months (95% CI 59-not reached) vs. 55 months (44-67), HR: 0·64, 95% CI: 0·42-0·99, P = 0·0435], with evidence of a detrimental impact with MYC rearrangement (LRT: P = 0·021). Twenty-one (24·7%) cyclophosphamide patients received an ASCT post-trial, median OS was not reached (95% CI: 39-not reached) for these participants compared to 31 months (22-39), in those who did not receive a post-trial ASCT. The analysis further supports the benefit of salvage ASCT, which may still be beneficial after second relapse in surviving patients. There is evidence that this benefit reduces in cytogenetic high-risk patients, highlighting the need for targeted study in this patient group.
引用
- Cook G, Royle KL, O'Connor S, et al. The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long-term follow-up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. Br J Haematol. 2019. PMID: 30729512. doi:10.1111/bjh.15782
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。